INMB INmune Bio, Inc. Stock Quote

INMB [NASD]

Index	-	P/E	-	EPS (ttm)	-1.12	Insider Own	40.59%	Shs Outstand	14.32M	Perf Week	13.52%
Market Cap	254.54M	Forward P/E	-	EPS next Y	-2.09	Insider Trans	-0.34%	Shs Float	10.48M	Perf Month	77.11%
Income	-14.60M	PEG	-	EPS next Q	-0.34	Inst Own	8.90%	Short Float	9.17%	Perf Quarter	17.26%
Sales	0.01M	P/S	17064.90	EPS this Y	-35.00%	Inst Trans	55.83%	Short Ratio	5.57	Perf Half Y	94.11%
Book/sh	4.44	P/B	4.01	EPS next Y	-47.20%	ROA	-33.80%	Target Price	29.50	Perf Year	224.23%
Cash/sh	3.17	P/C	5.62	EPS next 5Y	-	ROE	-35.30%	52W Range	4.50 - 29.99	Perf YTD	3.37%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-40.65%	Beta	-
Dividend %	-	Quick Ratio	22.40	Sales past 5Y	-	Gross Margin	-	52W Low	295.56%	ATR	1.31
Employees	5	Current Ratio	22.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	68.42	Volatility	9.04% 10.21%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-65.10%	Profit Margin	-	Rel Volume	1.52	Prev Close	18.01
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 05 AMC	Payout	-	Avg Volume	172.67K	Price	17.80
Recom	1.70	SMA20	24.09%	SMA50	42.26%	SMA200	37.50%	Volume	259,020	Change	-1.17%

Apr-21-21

Initiated

B. Riley Securities

Buy

$29

Jan-22-21

Reiterated

Maxim Group

Buy

$16 → $32

Sep-01-20

Initiated

BTIG Research

Buy

$23

Jul-15-20

Reiterated

H.C. Wainwright

Buy

$7 → $20

Jun-14-21 04:01PM	INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution GlobeNewswire
Jun-13-21 10:59PM	Where Do Hedge Funds Stand On Inmune Bio Inc. (INMB)? Insider Monkey
Jun-02-21 09:00AM	INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN GlobeNewswire
May-24-21 09:00AM	INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021 GlobeNewswire -7.75%
May-06-21 04:01AM	INmune Bio, Inc. (INMB) Q1 2021 Earnings Call Transcript Motley Fool -5.51%
May-05-21 04:15PM	INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update GlobeNewswire
02:45PM	INmune Bio, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 09:00AM	INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5 GlobeNewswire
Apr-26-21 09:00AM	INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference GlobeNewswire
04:16AM	What Type Of Shareholders Make Up INmune Bio, Inc.'s (NASDAQ:INMB) Share Registry? Simply Wall St.
Mar-22-21 09:00AM	INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings GlobeNewswire
Mar-08-21 09:00AM	INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 GlobeNewswire -8.32%
Mar-05-21 07:30PM	INmune Bio, Inc. (INMB) Q4 2020 Earnings Call Transcript Motley Fool -6.90%
Mar-04-21 04:15PM	INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update GlobeNewswire -18.37%
02:30PM	INmune Bio, Inc. to Host Earnings Call ACCESSWIRE
Feb-25-21 09:00AM	INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4 GlobeNewswire
Jan-25-21 01:50AM	We Think INmune Bio (NASDAQ:INMB) Can Easily Afford To Drive Business Growth Simply Wall St.
Jan-21-21 03:53PM	Why INmune Bio Stock Soared Then Sank Today Motley Fool -18.95%
08:05AM	The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping Benzinga
07:00AM	INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimers Disease in Phase 1b Trial GlobeNewswire
Jan-13-21 08:00AM	INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET GlobeNewswire +11.10%
Nov-27-20 10:59AM	Do Hedge Funds Love Inmune Bio Inc. (INMB)? Insider Monkey +5.19%
Nov-17-20 10:33AM	Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors PR Newswire +8.02%
Nov-09-20 07:00AM	INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor for Pulmonary Complications in COVID-19 Patients GlobeNewswire
Nov-05-20 04:00PM	INmune Bio, Inc. Announces Third Quarter Results and Provides Business Update GlobeNewswire
Oct-29-20 08:30AM	INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5 GlobeNewswire
Oct-26-20 07:51AM	Do Insiders Own Lots Of Shares In INmune Bio, Inc. (NASDAQ:INMB)? Simply Wall St.
Oct-05-20 09:00AM	INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimers Drug Discovery GlobeNewswire
Sep-23-20 06:00AM	INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29 GlobeNewswire
Sep-16-20 07:00AM	INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression GlobeNewswire +6.70%
Sep-14-20 07:00AM	INmune Bio, Inc. to Participate in Oppenheimers Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September 23, 2020. GlobeNewswire +5.18%
Sep-03-20 09:00AM	INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune Therapy GlobeNewswire
Sep-01-20 09:00AM	INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 Patients GlobeNewswire
Aug-13-20 09:00AM	European Patent Granted Covering INmune Bios XPro1595 GlobeNewswire
Aug-05-20 04:01PM	INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update GlobeNewswire
Aug-03-20 07:00AM	INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020 GlobeNewswire
Jul-31-20 07:00AM	INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results GlobeNewswire
Jul-27-20 07:00AM	INmune Bio, Inc. Featured on Fox News (VIDEO): STNF and Cytokine Storm GlobeNewswire -8.54%
Jul-20-20 04:57PM	Correction: INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters Over-Allotment Option GlobeNewswire +26.28%
01:07PM	INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters Over-Allotment Option GlobeNewswire
Jul-16-20 09:15AM	INmune Bio, Inc. Prices Public Offering of Common Stock GlobeNewswire -17.78%
Jul-15-20 04:10PM	INmune Bio, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire -17.14%
Jul-14-20 04:16PM	Tiny Biotech Skyrockets To A Record High On Promising Alzheimer's News Investor's Business Daily +77.97%
08:04AM	The Daily Biotech Pulse: Blueprint, Roche Ink $1.7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits Benzinga
Jul-13-20 04:16PM	INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimers Disease GlobeNewswire +26.43%
Jul-09-20 09:00AM	INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimers Disease Prior to Start of AAIC 2020 GlobeNewswire +17.31%
Jun-24-20 05:21AM	Neurotez: Can Leptin Prove Beneficial for Alzheimer's Patients? Zacks Small Cap Research -7.81%
Jun-11-20 09:00AM	INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS GlobeNewswire
May-19-20 09:00AM	Killers at the Crossroad A Published Review of Innate Immune Cell Potential in Treatment of Cancers Published by Co-Founder and CSO of INmune Bio, Inc. GlobeNewswire
May-14-20 09:00AM	INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update GlobeNewswire +11.67%
May-11-20 09:00AM	INmune Bio Incs INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response in Pre-clinical Models of Trastuzumab-Resistant HER2+ Breast Cancer GlobeNewswire
May-06-20 04:20PM	INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call GlobeNewswire
Apr-28-20 09:00AM	INmune Bio, Inc. to Speak on COVID-19 Therapeutic Panel at Maxim Groups Infectious Disease Virtual Conference on May 5, 2020 GlobeNewswire
08:09AM	Is INmune Bio (NASDAQ:INMB) In A Good Position To Invest In Growth? Simply Wall St.
Apr-23-20 09:00AM	Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNFs Impact on Breast Cancer GlobeNewswire
Apr-22-20 10:55AM	INMB: Evaluating DN-TNF as COVID-19 Treatment Zacks Small Cap Research
09:00AM	INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells GlobeNewswire
Apr-20-20 09:00AM	INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Companys TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19 GlobeNewswire +7.74%
Mar-16-20 05:35AM	INMB: Multiple Milestones Ahead in 2020 Zacks Small Cap Research -11.63%
Mar-11-20 09:00AM	INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimers Disease and NASH GlobeNewswire +26.32%
Mar-05-20 09:00AM	INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17 GlobeNewswire
Feb-27-20 09:00AM	INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results GlobeNewswire
Feb-10-20 09:08AM	INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS GlobeNewswire
Jan-29-20 08:25AM	Have Insiders Been Buying INmune Bio Inc. (NASDAQ:INMB) Shares? Simply Wall St.
Jan-02-20 09:00AM	INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals GlobeNewswire +6.09%
Dec-17-19 09:00AM	INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03, Demonstrates Efficacy and Safety; INB03 is Advancing to Phase II Trials GlobeNewswire +11.76%
Dec-02-19 09:00AM	INmune Bio, Inc. Announces First Alzheimers Disease Patient Dosed in XPro1595 Study GlobeNewswire
Nov-26-19 06:00AM	INmune Bio Inc. to Discuss Potential New Alzheimers Disease Treatments in CTAD Pre-Conference Webinar GlobeNewswire +6.95%
Nov-25-19 08:05AM	INMB: Potential Link Between Obesity and Neuroinflammation Shown in Mouse Model of Alzheimers Zacks Small Cap Research
Nov-19-19 09:00AM	INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen GlobeNewswire
Nov-08-19 04:00PM	INmune Bio, Inc. Reports Third Quarter 2019 Financial Results and Provides Shareholder Update GlobeNewswire
Oct-21-19 03:00PM	INmune Bio, Inc. Announces Potentially Strong Link Between Obesity and Alzheimer's Disease at the Society for Neuroscience 49th Annual Meeting GlobeNewswire +13.79%
10:42AM	Here's Why We're Not Too Worried About INmune Bio's (NASDAQ:INMB) Cash Burn Situation Simply Wall St.
Oct-17-19 09:00AM	INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neurosciences Annual Meeting GlobeNewswire +12.23%
Oct-08-19 09:00AM	INmune Bio Inc. to Present at Advances in Immuno-Oncology USA Congress and at World Immunotherapy Congress in October GlobeNewswire -6.56%
Sep-24-19 10:20AM	CEO of INmune Bio Inc. Discusses Company Accomplishments at Nasdaqs MarketSite and Announces Presentation at World Immunotherapy Congress GlobeNewswire
Sep-23-19 09:03AM	INmune Bio to Present XPro1595 for Treating Neuroinflammation in Alzheimers Disease at 2019 Alzheimers Association International Conference (AAIC) Satellite Symposium GlobeNewswire
Sep-20-19 10:02AM	6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day Zacks
Sep-17-19 09:05AM	INmune Bio Invited to Speak on Companys Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress GlobeNewswire
Sep-12-19 08:30AM	INmune Bio Inc. Announces USPTO Allowance of Key Patent Covering Its DN-TNFa Platform Technology for Treating Cancer GlobeNewswire
Sep-05-19 08:33AM	INmune Bio to Present at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September 10th at 2:10 p.m. ET GlobeNewswire
Sep-04-19 09:06AM	INmune Bio Inc. to Introduce NeuLiv Program for Treatment of NASH at H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire +7.53%
Aug-21-19 02:25PM	Read This Before Selling INmune Bio Inc. (NASDAQ:INMB) Shares Simply Wall St. -7.24%
10:30AM	INMB: Positive Preliminary Phase 1 Data for INB03 Zacks Small Cap Research
Aug-13-19 07:25AM	The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results Benzinga
Aug-12-19 09:01AM	INmune Bio Reports Second Quarter 2019 Financial Results and Provides Shareholder Update GlobeNewswire -7.84%
Aug-08-19 08:30AM	INmune Bio Appoints Biotechnology Executive Edgardo Baracchini as New Board Member GlobeNewswire -7.89%
Aug-06-19 03:40PM	Biotech Stocks to Watch Through the 2nd Half of 2019 GuruFocus.com
Aug-05-19 09:01AM	INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer GlobeNewswire
Aug-01-19 09:01AM	INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institutes 7th Annual Immuno-Oncology Summit GlobeNewswire
Jul-25-19 09:01AM	INmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Science & Technology 2019 GlobeNewswire
Jul-03-19 09:01AM	INmune Bio Co-Founder and CEO Presents at Maxim Groups Conference on Alzheimers Disease GlobeNewswire
Jun-27-19 09:03AM	INmune Bio Announces Publication of Data on INKmune Primed NK cells in Peer-Reviewed Journal PLOS ONE GlobeNewswire +5.31%
Jun-11-19 08:30AM	INmune Bio Inc. Featured in Exclusive NetworkNewsWire Broadcast GlobeNewswire +5.09%
Jun-10-19 01:35PM	INMB: TNF- Inhibition Associated with Decreased Risk of Developing Alzheimers Disease Zacks Small Cap Research
Jun-04-19 04:45PM	INmune Bio to present Alzheimers Drug Candidate XPro1595 at The TNF Conference GlobeNewswire
May-28-19 09:03AM	INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th GlobeNewswire
May-22-19 10:00AM	INMB: Two Additional Clinical Trials Set to Initiate in 2019 Zacks Small Cap Research +10.95%
May-16-19 09:04AM	INmune Bio Announces Common Stock Purchase Agreement for up to $20.0 Million with Lincoln Park Capital GlobeNewswire
May-15-19 09:03AM	INmune Bio Reports First Quarter 2019 Financial Results and Provides Shareholder Update GlobeNewswire

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in La Jolla, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schroeder Timothy j	Director	Jun 14	Sale	19.02	10,000	190,200	136,667	Jun 15 04:09 PM
Schroeder Timothy j	Director	Jun 10	Sale	17.01	10,000	170,054	146,667	Jun 14 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience